Manager/Senior Manager

Kura Oncology has reported early commercial momentum for KOMZIFTI (ziftomenib), its once-daily oral menin inhibitor for relapsed or refractory acute myeloid leukaemia with NPM1 mutations. The drug generated $2.1 million in net revenue during the fourth quarter of 2025, based on approximately five weeks of sales following FDA approval on 13 November. The company achieved approximately 80% private payer coverage within 90 days of launch, with policies aligned to the label without additional restrictions. FDA Orange Book patent listings extend to 2044, supporting long-term market exclusivity. Kura reported $667.2 million in cash, cash equivalents and short-term investments, with an additional $180 million in anticipated collaboration payments, including a $135 million milestone from Kyowa Kirin. The company expects multiple clinical data milestones in 2026 across its AML and solid tumour programmes.

Kura Oncology has received a $135 million milestone payment from Kyowa Kirin following the first US commercial sale of KOMZIFTI™. The payment was triggered under the companies' collaboration and licence agreement. The milestone represents a significant commercial achievement for the partnership between the two pharmaceutical companies. KOMZIFTI has now entered the US market, marking an important step in the drug's commercialisation.

Kura Oncology receives $30 million development milestone payment in ziftomenib AML program with Kyowa Kirin. - Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program- SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced receipt of a $30 million milestone payment under its collaboration agreement with Kyowa Kirin in connection with the dosing of the first patient in the KOMET-017 Phase 3 registrational trials of ziftomenib, a once-daily, investigational oral menin inhibitor. Kura and Kyowa Kirin announced the launch of the KOMET-017 trials on September 29, 2025. KOMET-017 (NCT07007312) comprises two independent, global, randomized double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). Kura believes KOMET-017 is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura's pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn. Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding the therapeutic potential of ziftomenib and the KOMET-017 trial being the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, the risk that the collaboration with Kyowa Kirin is unsuccessful, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Kura Contact